Postdoctoral Fellows

Marleen Keyaerts

Medical Doctor (Nuclear Medicine)
PhD in Medical Sciences

PhD Thesis:
Title: Sensitive and accurate bioluminescence imaging: Influencing factors in cells and mice
Author: Marleen Keyaerts
Promotion Year: 2011
Promotor: Tony Lahoutte
Co-promotor: Vicky Caveliers

  • In Vivo Cellular and Molecular Imaging Lab (ICMI)
  • Nuclear Medicine (NUGE)

Research Focus:
  • Translational imaging using VHH
  • Immuno-oncology

Contributions to science:
During my PhD, my focus was on an emerging reporter gene imaging technique, Bioluminescence Imaging. I have published multiple papers describing crucial aspects and potential pitfalls of this technique, which allow researchers to better understand this technique.
  • Bioluminescence imaging: looking beyond the light. Keyaerts M, Caveliers V, Lahoutte T. Trends Mol Med. 2012, Mar;18(3):164-72.
  • Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo Imaging. Keyaerts M, Remory I, Caveliers V, Breckpot K, Bos TJ, Poelaert J, Bossuyt A, Lahoutte T. PLoS ONE. 2012 Jan; 7(1): e30061. doi:10.1371/journal.pone.0030061
  • Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, Vanhove C, Caveliers V, Bossuyt A, Lahoutte T. Eur J Nucl Med Mol Imaging. 2008 May;35(5):999-1007.
The ICMI lab has focused on VHH (nanobodies) as tools for molecular imaging and therapy. I was involved in the preclinical development.
  • SPECT Imaging with (99m)Tc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression. Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H, Lahoutte T. Mol Imaging Biol. 2008 May-Jun;10(3):167-75.
  • Synthesis, preclinical validation, dosimetry and toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. Xavier C, Vaneycken I, D’huyvetter M, Heemskerk J, Keyaerts M, Vincke C, Devoogdt N, Muyldermans S, Lahoutte T, Caveliers V. J Nucl Med. 2013 May;54(5):776-84
  • Targeted alpha therapy using short-lived alpha- particles and the promise of nanobodies as targeting vehicle. Dekempeneer Y, Keyaerts M, Krasniqi M, Puttemans J, Muyldermans S, Lahoutte T, D’huyvetter M, Devoogdt N. Expert Opin Biol Ther. 2016 Aug;16(8):1035-47
Since my nuclear medicine training in the UZ Brussel started, I have been actively involved in the translation of nanobodies in clinical trials. This is currently one of my main focuses, beside imaging and therapy in the field of immuno-oncology and immune checkpoint inhibition therapy.
  • Phase I study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2-expression in breast carcinoma. Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. J Nucl Med. 2016 Jan;57(1):27-33.

Complete List of Published Work:

Vrije Universiteit Brussel
Department BEFY, Labo ICMI, Building K
Laarbeeklaan 103
1090 Jette (Brussels)

UZ Brussel
Department of Nuclear Medicine
Laarbeeklaan 101
1090 Jette (Brussels)

Labo ICMI: 0032 (0)2 477 49 91
UZ Brussel: 0032 (0)2 477 50 20